Proposed FDA nanotech programme would develop best practices for industry
This article was originally published in Clinica
Executive Summary
The FDA’s National Center for Toxicological Research (NCTR) would be the “ideal candidate” for studying the safety of nanotech materials used in medical devices, drugs and biologics, Senator Mark Pryor said on introducing legislation into Congress on nanotech safety.